VEGFA and glioblastoma: In a biomarker analysis of AVAglio, the ‘proneural’ gene expression subtype was associated with a significant OS advantage (17.1 vs. 12.8 months) in newly diagnosed GBM receiving bevacizumab, which seems counterintuitive as this subtype is associated with lower VEGF expression, and the results could not be confirmed in the GLARIUS trial [46, 127, 158, 160].